Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report)'s share price passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $4.62 and traded as low as $3.85. Voyager Therapeutics shares last traded at $3.91, with a volume of 214,629 shares changing hands.
Wall Street Analyst Weigh In
VYGR has been the topic of several research analyst reports. HC Wainwright reissued a "buy" rating and issued a $30.00 target price on shares of Voyager Therapeutics in a report on Thursday, March 13th. StockNews.com downgraded shares of Voyager Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, December 13th. Cantor Fitzgerald restated an "overweight" rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Wells Fargo & Company set a $10.00 price target on Voyager Therapeutics and gave the company an "overweight" rating in a research note on Wednesday, March 12th. Finally, Wedbush restated an "outperform" rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $13.97.
Read Our Latest Research Report on Voyager Therapeutics
Voyager Therapeutics Stock Performance
The company has a market cap of $201.51 million, a PE ratio of 5.14 and a beta of 0.99. The company has a fifty day moving average of $4.51 and a two-hundred day moving average of $5.65.
Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.24). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The business had revenue of $4.39 million during the quarter, compared to analysts' expectations of $16.58 million. During the same quarter in the previous year, the company posted $1.25 earnings per share. On average, equities analysts forecast that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC bought a new stake in Voyager Therapeutics during the 4th quarter valued at about $29,000. Tower Research Capital LLC TRC increased its holdings in Voyager Therapeutics by 133.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company's stock worth $31,000 after purchasing an additional 3,077 shares during the period. Picton Mahoney Asset Management raised its position in Voyager Therapeutics by 71.1% during the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company's stock valued at $33,000 after purchasing an additional 2,444 shares in the last quarter. Oxford Asset Management LLP purchased a new stake in shares of Voyager Therapeutics in the 4th quarter worth $60,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Voyager Therapeutics in the 3rd quarter worth $74,000. 48.03% of the stock is currently owned by institutional investors.
Voyager Therapeutics Company Profile
(
Get Free Report)
Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.
See Also
Before you consider Voyager Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.
While Voyager Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
